Avidity Biosciences (RNA) Competitors $29.36 +0.90 (+3.16%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$29.54 +0.18 (+0.60%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNA vs. ITCI, GMAB, RDY, ASND, VTRS, QGEN, MRNA, BPMC, VRNA, and BBIOShould you be buying Avidity Biosciences stock or one of its competitors? The main competitors of Avidity Biosciences include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), Moderna (MRNA), Blueprint Medicines (BPMC), Verona Pharma PLC American Depositary Share (VRNA), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry. Avidity Biosciences vs. Its Competitors Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris Qiagen Moderna Blueprint Medicines Verona Pharma PLC American Depositary Share BridgeBio Pharma Avidity Biosciences (NASDAQ:RNA) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations. Does the media prefer RNA or ITCI? In the previous week, Avidity Biosciences had 5 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 5 mentions for Avidity Biosciences and 0 mentions for Intra-Cellular Therapies. Avidity Biosciences' average media sentiment score of 0.55 beat Intra-Cellular Therapies' score of 0.00 indicating that Avidity Biosciences is being referred to more favorably in the media. Company Overall Sentiment Avidity Biosciences Positive Intra-Cellular Therapies Neutral Which has stronger earnings & valuation, RNA or ITCI? Intra-Cellular Therapies has higher revenue and earnings than Avidity Biosciences. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Avidity Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvidity Biosciences$10.90M324.63-$322.30M-$3.00-9.79Intra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64 Is RNA or ITCI more profitable? Intra-Cellular Therapies has a net margin of -14.07% compared to Avidity Biosciences' net margin of -4,136.00%. Intra-Cellular Therapies' return on equity of -9.93% beat Avidity Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Avidity Biosciences-4,136.00% -26.96% -24.57% Intra-Cellular Therapies -14.07%-9.93%-8.38% Do analysts prefer RNA or ITCI? Avidity Biosciences presently has a consensus target price of $65.59, suggesting a potential upside of 123.39%. Intra-Cellular Therapies has a consensus target price of $109.70, suggesting a potential downside of 16.81%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Avidity Biosciences is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avidity Biosciences 0 Sell rating(s) 0 Hold rating(s) 16 Buy rating(s) 1 Strong Buy rating(s) 3.06Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 Which has more volatility & risk, RNA or ITCI? Avidity Biosciences has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Do insiders and institutionals have more ownership in RNA or ITCI? 92.3% of Intra-Cellular Therapies shares are held by institutional investors. 3.8% of Avidity Biosciences shares are held by insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryAvidity Biosciences beats Intra-Cellular Therapies on 10 of the 17 factors compared between the two stocks. Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNA vs. The Competition Export to ExcelMetricAvidity BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.43B$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-9.7921.3126.2319.90Price / Sales324.63278.47413.23113.66Price / CashN/A41.4736.1356.90Price / Book2.467.518.045.38Net Income-$322.30M-$55.05M$3.15B$248.50M7 Day Performance-1.58%2.07%1.44%2.04%1 Month Performance-14.68%4.84%3.62%4.84%1 Year Performance-21.10%5.37%34.68%20.23% Avidity Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNAAvidity Biosciences2.1929 of 5 stars$29.36+3.2%$65.59+123.4%-24.3%$3.43B$10.90M-9.79190ITCIIntra-Cellular Therapies0.9247 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.8892 of 5 stars$20.68-2.3%$39.17+89.4%-17.9%$13.57B$3.12B15.222,682High Trading VolumeRDYDr. Reddy's Laboratories2.8228 of 5 stars$15.31+0.5%$16.95+10.7%-2.3%$12.71B$3.81B23.2027,811ASNDAscendis Pharma A/S3.5796 of 5 stars$175.78-0.6%$220.67+25.5%+27.0%$10.81B$393.54M-27.991,017Positive NewsVTRSViatris3.0627 of 5 stars$8.85-0.2%$10.40+17.5%-10.5%$10.41B$14.74B3.5832,000QGENQiagen3.7836 of 5 stars$46.72-0.1%$47.74+2.2%+22.8%$10.39B$1.98B117.145,765Dividend AnnouncementMRNAModerna4.3651 of 5 stars$25.67-0.9%$46.61+81.6%-74.1%$10.02B$3.24B0.005,800Trending NewsOptions VolumeBPMCBlueprint Medicines1.5574 of 5 stars$128.40+0.2%$128.06-0.3%+16.2%$8.28B$508.82M-51.98640High Trading VolumeVRNAVerona Pharma PLC American Depositary Share2.5901 of 5 stars$97.05+2.9%$101.10+4.2%+482.7%$8.03B$42.28M-48.5330Positive NewsAnalyst ForecastBBIOBridgeBio Pharma4.7146 of 5 stars$42.17+1.1%$56.67+34.4%+71.9%$7.92B$221.90M0.00400Analyst ForecastInsider Trade Related Companies and Tools Related Companies Intra-Cellular Therapies Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Ascendis Pharma A/S Competitors Viatris Competitors Qiagen Competitors Moderna Competitors Blueprint Medicines Competitors Verona Pharma PLC American Depositary Share Competitors BridgeBio Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNA) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredMake 22x more from this summer’s Bitcoin boomBitcoin is on fire again. Wall Street’s piling in. ETFs are smashing volume records. And regular investors ...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
